Journal article icon

Journal article

Sodium-glucose co-transporter-2 (SGLT2) inhibitors: comparing trial and real world use (study protocol)

Abstract:

Sodium-glucose co-transporter-2 (SGLT2) inhibitors (gliflozins) are the newest class of medication available to treat type 2 diabetes (T2DM). Recent findings from the first complete cardiovascular safety trial in SGLT2 inhibitors, the Empagliflozin, Cardiovascular Outcomes, and Mortality in type 2 diabetes (EMPA-REG OUTCOMES) trial, demonstrated reduced cardiovascular outcomes in people with high cardiovascular risk. How to apply these findings to clinical practice remains unclear, with quest...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Publisher copy:
10.1007/s13300-017-0229-8

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Primary Care Health Sciences
Department:
Unknown
Role:
Author
ORCID:
0000-0002-8553-2641
Publisher:
Springer
Journal:
Diabetes Therapy More from this journal
Volume:
8
Issue:
2
Pages:
355-363
Publication date:
2017-01-30
Acceptance date:
2017-03-15
DOI:
EISSN:
1869-6961
ISSN:
1869-6953
Pmid:
28138853
Language:
English
Keywords:
Pubs id:
pubs:1013757
UUID:
uuid:f8efa174-0fc5-4769-be36-84a5fdf10753
Local pid:
pubs:1013757
Source identifiers:
1013757
Deposit date:
2019-10-29

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP